Renal or hepatic impairment. Monitor LFTs and blood counts regularly. Increased risk of cholelithiasis, pancreatitis, skeletal muscle effects. Withdraw treatment if no adequate response after 2 mth of treatment at max recommended dose.
Adult: PO : Standard micronised formulation: Initially, 200 mg once daily.
For non-micronised formulations: Initial: 200-300 mg/day in divided doses. Usual range: 200-400 mg/day.
Formulation w/ improved bioavailability: 40-160 mg once daily may be used.